Questions about
DUPIXENT? We can help.

DUPIXENT is the first and only treatment for EoE patients as young as 1 year old, weighing at least 15 kg. DUPIXENT is a biologic that inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation contributing to EoE. DUPIXENT is not an immunosuppressant. The mechanism of dupilumab action has not been definitively established.^1,2

LEARN MORE ABOUT
HOW DUPIXENT WORKS

DUPIXENT has a unique mechanism of action in EoE. It is the first and only FDA-approved dual inhibitor of IL-4 and IL-13 signaling, inhibiting two of the key drivers of type 2 inflammation contributing to EoE. The mechanism of dupilumab action has not been definitively established.^1,2

VIEW THE UNIQUE
mechanism OF ACTION

DUPIXENT is not a steroid. DUPIXENT is a biologic that inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation contributing to EoE. The mechanism of dupilumab action has not been definitively established.^1,2

EXPLORE THE
mechanism OF ACTION

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).¹

VIEW THE EFFICACY data

In addition to EoE, DUPIXENT is also indicated in 5 additional conditions driven in part by type 2 inflammation: uncontrolled moderate-to-severe atopic dermatitis (6+ months of age), uncontrolled moderate-to-severe eosinophilic or OCS-dependent asthma (6+ years of age [Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus]), inadequately controlled chronic rhinosinusitis with nasal polyps (12+ years of age), prurigo nodularis (18+ years of age), and inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype (18+ years of age [Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm]).¹

LEARN MORE

The efficacy and safety of DUPIXENT was evaluated for up to 52 weeks in two multipart, phase 3 clinical trials.

ADULTS & ADOLESCENTS AGED 12+ YEARS

Study design: Part A and Part B each consisted of a 24-week double-blind treatment period. Subjects who completed Part A or Part B were then eligible to enroll in a 28-week extended active treatment period (Part A-C or Part B-C, respectively) totaling 52 weeks of treatment.^1,3,4

Overview: A total of 188 subjects aged 12+ years were enrolled in the extended active treatment period (77 in Part A-C and 111 in Part B-C). Management of the disease was evaluated through clinical, histologic, and endoscopic endpoints.^1,3

CHILDREN AGED 1-11 YEARS

Study design: EoE KIDS-Part A consisted of a 16-week double-blind treatment period. Subjects who completed Part A were then eligible to enroll in a 36-week extended active treatment period (EoE KIDS-Part B) totaling 52 weeks of treatment.¹

Overview: A total of 47 subjects aged 1-11 years were enrolled in the extended active treatment period. Management of the disease was evaluated through clinical, histologic, and endoscopic endpoints.¹

VIEW THE study design IN
ADULTS & ADOLESCENTS
(12+ YEARS)

VIEW THE study design IN
CHILDREN (1-11 YEARS)

ADULTS & ADOLESCENTS AGED 12+ YEARS

Reductions in DSQ total score were first observed at Week 4 with treatment with DUPIXENT 300 mg QW (post-hoc analysis; results are descriptive).³

• Part A: 28% reduction (-9 points) from baseline with DUPIXENT (n=42) vs 11% reduction (-4 points) with placebo (n=39)
• Part B: 31% reduction (-12 points) from baseline with DUPIXENT (n=80) vs 16% reduction (-6 points) with placebo (n=79)

DUPIXENT significantly reduced DSQ total scores compared to placebo at Week 24 (coprimary endpoint).³

• Part A: 69% reduction (-21.9 points) from baseline with DUPIXENT (n=42) vs 32% reduction (-9.6 points) with placebo (n=39) (P<0.001)
• Part B: 64% reduction (-23.8 points) from baseline with DUPIXENT (n=80) vs 41% reduction (-13.9 points) with placebo (n=79) (P<0.0001)

DSQ total score reductions were observed for up to 52 weeks with continued weekly DUPIXENT treatment (secondary endpoint).³

• Part A-C: 76% reduction (-23.4 points) from baseline after 52 weeks of treatment with DUPIXENT (n=29) and 66% reduction (-21.7 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=23)
• Part B-C: 81% reduction (-30.3 points) from baseline after 52 weeks of treatment with DUPIXENT (n=54) and 78% reduction (-27.3 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=24)

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.³

Total biweekly DSQ scores range from 0 to 84; higher scores indicate greater frequency and severity of dysphagia.¹

ADULTS & ADOLESCENTS AGED 12+ YEARS

DUPIXENT demonstrated greater histologic improvements compared to placebo at Week 24.^1,3

Histologic improvements were observed at Week 52 with continued weekly DUPIXENT treatment.³

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.³

^aCoprimary endpoint at Week 24;
secondary endpoint at Week 52.^1,3

^bSecondary endpoint at Weeks 24 and 52. In Part B, this endpoint was ordered after the point at which hierarchical testing procedure failed; results are descriptive.³

To be eligible to participate in the study, all participants must have had uncontrolled EoE as defined by ≥15 intraepithelial EOS/HPF despite an 8-week course of a high-dose PPI and a Dysphagia Symptom Questionnaire (DSQ) score of ≥10.^1,4

CHILDREN AGED 1-11 YEARS

DUPIXENT demonstrated greater histologic improvements compared to placebo at Week 16.^1,3

Histologic improvements were defined as the proportion of participants who achieved peak esophageal intraepithelial eosinophil counts of <15 EOS/HPF (histologic response) or ≤6 EOS/HPF (histologic remission).¹

Histologic responses were maintained at Week 52 with continued DUPIXENT treatment.³

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.³

^cPrimary endpoint at Week 16; secondary endpoint at Week 52.³

^dSecondary endpoint at Weeks 16 and 52.³

To be eligible to participate in the study, all participants must have had uncontrolled EoE as defined by ≥15 intraepithelial EOS/HPF despite an 8-week course of a high-dose PPI and a history of EoE signs and symptoms.^1,3

ADULTS & ADOLESCENTS AGED 12+ YEARS

Visible changes in the esophagus were observed at Week 24.^3,a

• Part A: 49% reduction (-3.2 points) from baseline with DUPIXENT (n=42) vs 5% reduction (-0.3 points) with placebo (n=39)
• Part B: 66% reduction (-4.5 points) from baseline with DUPIXENT (n=80) vs 8% reduction (-0.6 points) with placebo (n=79)

EREFS total score was reduced at Week 52 with continued weekly DUPIXENT treatment.^3,a

• Part A-C: 63% reduction (-4.1 points) from baseline after 52 weeks of treatment with DUPIXENT (n=35) and 65% reduction (-3.9 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=30)
• Part B-C: 77% reduction (-5.3 points) from baseline after 52 weeks of treatment with DUPIXENT (n=63) and 76% reduction (-6.1 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=37)

Extended active treatment period, results are descriptive at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.

^aSecondary endpoint at Weeks 24 and 52. Results are descriptive; thresholds for clinically meaningful changes in EREFS scores have not been established. Additionally, in Part B this endpoint was ordered after the point at which hierarchical testing procedure failed.

CHILDREN AGED 1-11 YEARS

DUPIXENT significantly improved the appearance of the esophagus at Week 16.^1,3,b

• EoE KIDS-Part A: 52% reduction (-3.6 points) from baseline with DUPIXENT (n=30) vs 0% worsening (0 points) with placebo (n=25) (P<0.0001)

EREFS total score was reduced at Week 52 with continued DUPIXENT treatment.^3,b

• EoE KIDS-Part B: 71% reduction (-4.9 points) from baseline with DUPIXENT (n=26) and 45% reduction (-3.3 points) from baseline after switching to DUPIXENT from placebo at Week 16 (n=13)

Thresholds for clinically meaningful changes in EREFS scores have not been established. Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.³

^aSecondary endpoint at Weeks 16 and 52.³

EREFS is an endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and strictures. Each feature is graded on its severity and is assigned an associated value. The EREFS total score (range: 0 to 18) is the composite value of the proximal and distal esophageal regions with each region scored from 0 to 9.^4-8

A higher score indicates greater disease severity.³

EREFS is an endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and strictures. Each feature is graded on its severity and is assigned an associated value. The EREFS total score (range: 0 to 18) is the composite value of the proximal and distal esophageal regions with each region scored from 0 to 9.^4-8

A higher score indicates greater disease severity.³

CHILDREN AGED 1-11 YEARS

Differences in the number of days with ≥1 sign or symptom of EoE via LSM change in PESQ-C were observed at Week 16.^3,a

• EoE KIDS-Part A: -0.21 reduction (~2.9 fewer days) from baseline with DUPIXENT (n=32) vs -0.16 reduction (~2.2 fewer days) with placebo (n=29)

A decrease in the number of days with ≥1 sign or symptom of EoE via LSM change in PESQ-C were observed at Week 52.^3,a

• EoE KIDS-Part B: -0.26 reduction (~3.6 fewer days) from baseline with DUPIXENT (n=22) and -0.39 reduction (~5.5 fewer days) from baseline after switching to DUPIXENT from placebo at Week 16 (n=7)

Definitive conclusions cannot be made. Numerical improvements were observed at Week 16 and maintained for 52 weeks. Results are descriptive at Week 52 due to limitations associated with extended active treatment design including lack of comparator arm and decreasing sample size.³

^aSecondary endpoint at Weeks 16 and 52.³

PESQ-C measures the signs and symptoms of EoE observed by a caregiver and measures 8 distinct signs and symptoms of EoE over a 14-day period^3,9:

Stomach
pain

Heartburn

Acid reflux

Regurgitation

Vomiting

Difficulty
swallowing

Food
getting stuck

Food
refusal

• Caregiver responses reflect what their child has told them, what they have directly observed, and/or what another caregiver has told them^3,9
• Total score ranges from 0 to 1. For example, if the patient has 7 days of symptoms over the 14-day period, their total score is 0.5 (calculated by 7 ÷ 14)^3,9

CHILDREN AGED 1-11 YEARS

Changes in body weight for age percentile were observed at Week 16.^3,a,b

• EoE KIDS-Part A: 2.2-percentile increase from baseline with DUPIXENT (n=32) vs 0.8-percentile increase with placebo (n=28)
• EoE KIDS-Part B: 6.0-percentile increase from baseline with DUPIXENT (n=30) and 5.3-percentile increase from baseline after switching to DUPIXENT from placebo at Week 16 (n=14)

Results are descriptive. Definitive conclusions cannot be made due to the exploratory nature of the results at Week 16, and lack of comparator arm and decreasing sample size at Week 52.³

^aExploratory endpoint at Week 16; secondary endpoint at Week 52.³

^bBody weight for age percentile, standardized by gender and age, is used to assess a child's weight compared to their peers.

DUPIXENT was studied in two multipart, phase 3 clinical trials.

ADULTS & ADOLESCENTS AGED 12+ YEARS

All enrolled subjects (81 in Part A and 159 in Part B^a) were required to have uncontrolled EoE—as defined by ≥15 EOS/HPF despite an 8-week course of a high-dose PPI and a Dysphagia Symptom Questionnaire (DSQ) score of ≥10.^1,3,4

The demographics and baseline characteristics were similar in Parts A and B. At baseline, 43% of subjects in Part A and 37% of subjects in Part B had a history of prior esophageal dilations. The mean age in years was 32 years (range, 13 to 62 years) in Part A and 28 years (range, 12 to 66 years) in Part B. The majority of subjects were male (60% in Part A and 68% in Part B) and White (96% in Part A and 90% in Part B). The mean baseline DSQ score (SD) was 33.6 (12.4) in Part A and 37.2 (10.7) in Part B.¹

^aDUPIXENT 300 mg Q2W was studied in Part B (n=81) and Part B-C (n=116). Patients from placebo arm in Part B were randomized to receive either DUPIXENT 300 mg Q2W (n=37) or DUPIXENT 300 mg QW (n=37) in Part B-C of the study. DUPIXENT 300 mg Q2W is not approved for the treatment of EoE.^1,3

CHILDREN AGED 1-11 YEARS

All enrolled subjects were required to have uncontrolled EoE—as defined by ≥15 EOS/HPF despite an 8-week course of a high-dose PPI and a history of EoE signs and symptoms.¹

The demographics and baseline characteristics were similar between treatment groups. At baseline, the mean age was 8 years (range, 1 to 11 years), the median weight was 28 kg, 75% of subjects were male, 85% identified as White, 12% as Black, 2% as Asian, and 2% identified as another racial subgroup.¹

Unless used as rescue medications, systemic and/or swallowed topical corticosteroids were prohibited in both clinical trials during the treatment period. Patients using PPIs during screening were to continue throughout the treatment period or stop prior to baseline.³

VIEW THE study design IN
ADULTS & ADOLESCENTS (12+ YEARS)

VIEW THE study design IN
CHILDREN (1-11 YEARS)

ADULTS & ADOLESCENTS AGED 12+ YEARS

In Parts A and B (n=122; 24-week safety pool), the most common adverse reactions (incidence ≥2%) were injection site reactions (38%),^a upper respiratory tract infections (18%),^b arthralgia (2%), and herpes viral infections (2%).^1,c

^a Injection site reactions include, but are not limited to, injection site swelling, pain, and bruising.¹

^b Upper respiratory tract infections are composed of several terms including, but not limited to, COVID-19, sinusitis, and upper respiratory tract infection.¹

^c Herpes viral infections are composed of oral herpes and herpes simplex.¹

Part A-C—Week 52: The most frequently reported TEAEs (in ≥5% of participants overall) were: injection site reaction (15.6%), injection site erythema (11.7%), injection site pain (6.5%), headache (6.5%), nasopharyngitis (5.2%), acne (5.2%), and insomnia (5.2%).³

Part B-C—Week 52: The most frequently reported TEAEs (in ≥5% of participants overall) were: injection site reaction (13.7%), injection site pain (8.4%), injection site erythema (6.6%), and COVID-19 (7.9%).³

CHILDREN AGED 1-11 YEARS

In EoE KIDS-Part A (n=32; 16-week safety data), the most common adverse events (incidence ≥2% and greater than placebo) were injection site erythema (13%), COVID-19 (9%)^d, viral gastroenteritis (6%), diarrhea (6%), pyrexia (6%), fatigue (6%), and rash (3%).³

^dAll cases were mild or moderate and did not lead to study discontinuation.³

The safety profile of DUPIXENT through Week 16 of the EoE KIDS clinical study was generally similar to the safety profile in adult and pediatric patients 12 years of age and older in EoE. In Part B, a helminth infection was reported in one DUPIXENT-treated subject.¹

ADULTS & ADOLESCENTS AGED 12+ YEARS

The safety profile of DUPIXENT in 72 pediatric subjects 12 to 17 years of age, weighing at least 40 kg, and adults in Parts A and B was similar.¹

CHILDREN AGED 1-11 YEARS

The safety profile of DUPIXENT through Week 16 of the EoE KIDS clinical study was generally similar to the safety profile in adult and pediatric patients 12 years of age and older in EoE. In Part B, a helminth infection was reported in one DUPIXENT-treated subject.¹

EXPLORE THE safety profile IN ADULTS & ADOLESCENTS (12+ YEARS)

VIEW THE safety profile IN CHILDREN (1-11 YEARS)

There is no requirement for initial lab testing or ongoing lab monitoring with DUPIXENT according to the Prescribing Information.¹

SEE PRESCRIBING INFORMATION

DUPIXENT is a medicine that is administered by subcutaneous injection. You may decide whether patients self-administer DUPIXENT at home, or you can administer in office.¹

Administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection. Be sure to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred.¹

DUPIXENT is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT after receiving training in subcutaneous injection technique using the 200 mg or 300 mg pre-filled syringe or 200 mg or 300 mg pre-filled pen. For pediatric patients 12 to 17 years of age, it is recommended that DUPIXENT be administered under the supervision of an adult. In children 1 year to less than 12 years of age, DUPIXENT should be given by a caregiver. There is no loading dose for EoE patients.¹

Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.¹

LEARN MORE ABOUT DOSING
AND ADMINISTRATION

The pre-filled syringe and the pre-filled pen each come with their own set of specific instructions and guidelines for administration. After choosing your preferred method of treatment, it is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use to ensure each step is followed correctly.¹

It is recommended that children 12 years of age and older administer DUPIXENT under the supervision of an adult. In children 1 year to less than 12 years of age, DUPIXENT should be given by a caregiver.¹

Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.¹

Advise patients to follow sharps disposal recommendations after administering DUPIXENT. Patients and/or caregivers should read the Instructions for Use prior to injecting.¹

Download the full Instructions for Use below.

DUPIXENT should be refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. If necessary, DUPIXENT may be kept at room temperature up to 77°F (25°C) for a maximum of 14 days. DUPIXENT should not be stored above 77°F (25°C). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded. Do not expose DUPIXENT to heat or direct sunlight. Do not freeze or shake.¹

• For the 200 mg/1.14 mL pre-filled pen or syringe, allow 30 minutes for DUPIXENT to reach room temperature¹
• For the 300 mg/2 mL pre-filled pen or syringe, allow 45 minutes for DUPIXENT to reach room temperature¹

SEE INFORMATION ON PREPARATION FOR USE, STORAGE, AND HANDLING OF DUPIXENT

• If a weekly dose is missed, administer the dose as soon as possible, and start a new weekly schedule from the date of the last administered dose.¹
• If an every other week dose is missed, administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.¹

LEARN MORE ABOUT DOSING
FOR DUPIXENT

DUPIXENT is not an immunosuppressant. DUPIXENT is a biologic that inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation contributing to EoE. The mechanism of dupilumab action has not been definitively established.¹

DISCOVER HOW DUPIXENT
WORKS

ADULTS & ADOLESCENTS AGED 12+ YEARS

DUPIXENT does not have a boxed warning. In Parts A and B (n=122; 24-week safety pool), the most common adverse reactions (incidence ≥2%) were injection site reactions (38%),^a upper respiratory tract infections (18%),^b arthralgia (2%), and herpes viral infections (2%).^1,c

^a Injection site reactions include, but are not limited to, injection site swelling, pain, and bruising.¹

^b Upper respiratory tract infections are composed of several terms including, but not limited to, COVID-19, sinusitis, and upper respiratory tract infection.¹

^c Herpes viral infections are composed of oral herpes and herpes simplex.¹

The safety profile of DUPIXENT in 72 pediatric subjects 12 to 17 years of age, weighing at least 40 kg, and adults in Parts A and B was similar.¹

CHILDREN AGED 1-11 YEARS

In EoE KIDS-Part A (n=32; 16-week safety data), the most common adverse events (incidence ≥5% and greater than placebo) were injection site erythema (13%), COVID-19 (9%),^d viral gastroenteritis (6%), diarrhea (6%), pyrexia (6%), and fatigue (6%).³

^dAll cases were mild or moderate and did not lead to study discontinuation.³

Note: Select Important Safety Information: Warnings and Precautions–Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme, have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

EXPLORE THE safety profile IN ADULTS & ADOLESCENTS (12+ YEARS)

VIEW THE safety profile IN CHILDREN (1-11 YEARS)

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT. It is unknown if administration of live vaccines during DUPIXENT treatment will impact the safety or effectiveness of these vaccines. Limited data are available regarding coadministration of DUPIXENT with non-live vaccines.¹

LEARN MORE ABOUT DOSING
AND ADMINISTRATION

DUPIXENT does NOT have any known drug-to-drug interactions. DUPIXENT is NOT metabolized through the liver or excreted through the kidneys.¹

ADULTS & ADOLESCENTS AGED 12+ YEARS

In Parts A and B (n=122; 24-week safety pool), the most common adverse reactions (incidence ≥2%) were injection site reactions (38%),^a upper respiratory tract infections (18%),^b arthralgia (2%), and herpes viral infections (2%).^1,c

^a Injection site reactions include, but are not limited to, injection site swelling, pain, and bruising.¹

^b Upper respiratory tract infections are composed of several terms including, but not limited to, COVID-19, sinusitis, and upper respiratory tract infection.¹

^c Herpes viral infections are composed of oral herpes and herpes simplex.¹

CHILDREN AGED 1-11 YEARS

In EoE KIDS-Part A (n=32; 16-week safety data), the most common adverse events (incidence ≥5% and greater than placebo) were injection site erythema (13%), COVID-19 (9%),^d viral gastroenteritis (6%), diarrhea (6%), pyrexia (6%), and fatigue (6%).³

^dAll cases were mild or moderate and did not lead to study discontinuation.³

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

EXPLORE THE safety results IN ADULTS & ADOLESCENTS (12+ YEARS)

VIEW THE safety results IN CHILDREN (1-11 YEARS)

No. Tuberculosis testing is not required with DUPIXENT according to the Prescribing Information.¹

SEE PRESCRIBING INFORMATION

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

To contact DUPIXENT MyWay, please call 1-844-DUPIXENT (1-844-387-4936). DUPIXENT MyWay coordinators are available Monday-Friday 8 am to 9 pm ET. The fax number is 1-844-387-9370.

When filling out the DUPIXENT MyWay Enrollment Form, both you and your patient will be required to supply information, such as the patient’s insurance, diagnosis, and prescription. You can email or print the enrollment forms below.

LEARN MORE ABOUT THE SUPPORT OFFERED BY DUPIXENT MyWay

You can visit DUPIXENT MyWay coverage support and resources webpage to find out about the prior authorization request and appeal process, if necessary.

In addition, CoverMyMeds support is available for DUPIXENT. It provides additional enrollment and prior authorization process-related support for DUPIXENT. Live support is available at 866-452-5017 or covermymeds.com.

NAVIGATING PRIOR AUTHORIZATIONS AND APPEALS FOR DUPIXENT

If you have a current process for prescribing biologics delivered through a specialty pharmacy, you can utilize that process to get DUPIXENT approved for your patients.

LEARN MORE ABOUT
DUPIXENT MyWay

Yes. DUPIXENT MyWay is committed to helping all eligible patients throughout the treatment process. At any time in the process, you or your patient can contact DUPIXENT MyWay for any needed support, such as help covering the cost of DUPIXENT or supplemental injection training. The DUPIXENT MyWay Case Manager will communicate directly with your patient and address any questions they may have about DUPIXENT, including the insurance process. While the insurance benefits for DUPIXENT are being confirmed, your patient will receive a Welcome Call from their DUPIXENT MyWay Case Manager.

LEARN MORE ABOUT
DUPIXENT MyWay

The amount your patients pay for DUPIXENT will largely depend on whether they have insurance, the type of insurance they have, whether their insurance provider considers the medication to be preferred or not preferred, and whether they’ve met their deductible.

GET PRICING INFORMATION YOU CAN SHARE WITH YOUR PATIENTS